Showing results (2091-2100 of 2,239) with videos related to

Sort By:
Pageof 224
Oncotarget|August 18, 2016
Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterationsNa-Na Lou, Xu-Chao Zhang, Hua-Jun Chen, et al.
Lung Cancer (Amsterdam, Netherlands)|August 27, 2024
Tumor immune microenvironment of NSCLC with EGFR exon 20 insertions may predict efficacy of first-line ICI-combined regimenKe-Jun Liu, Hong-Rui Li, Quan-Quan Tan, et al.
Science Progress|March 19, 2025
The combination of immune checkpoint inhibitor and chemotherapy may be efficacious for advanced non-small cell lung cancer with near-loop insertions of EGFR exon 20: A retrospective analysisKe-Jun Liu, Hong-Rui Li, Quan-Quan Tan, et al.
Cancer|November 27, 2019
Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancerVassiliki A Papadimitrakopoulou, Ji-Youn Han, Myung-Ju Ahn, et al.
Thoracic Cancer|July 7, 2018
Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancerJin Kang, Hua-Jun Chen, Xu-Chao Zhang, et al.
Chest|March 22, 2021
Modification of Pathologic T Classification for Non-small Cell Lung Cancer With Visceral Pleural Invasion: Data From 1,055 Cases of Cancers ≤ 3 cmRun-Bin Liang, Peng Li, Bob T Li, et al.
Frontiers in Oncology|October 31, 2022
Deep learning-based growth prediction for sub-solid pulmonary nodules on CT imagesRi-Qiang Liao, An-Wei Li, Hong-Hong Yan, et al.
Nature Biotechnology|October 9, 2018
Comprehensive identification of peptides in tandem mass spectra using an efficient open search engineHao Chi, Chao Liu, Hao Yang, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|May 24, 2014
Dihydroartemisinin accentuates the anti-tumor effects of photodynamic therapy via inactivation of NF-κB in Eca109 and Ec9706 esophageal cancer cellsYan Jing Li, Jian Hua Zhou, Xiao Xue Du, et al.
The Lancet. Oncology|July 26, 2011
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyCaicun Zhou, Yi-Long Wu, Gongyan Chen, et al.
Pageof 224